Literature DB >> 20679080

Photodynamic therapy for steroid-associated central serous chorioretinopathy.

Tae-Gon Lee1, Judy E Kim.   

Abstract

PURPOSE: To evaluate the short-term efficacy of photodynamic therapy (PDT) for steroid-associated chronic or recurrent central serous chorioretinopathy (CSC).
DESIGN: Interventional case series.
METHODS: Retrospective review of nine consecutive cases of steroid-associated CSC treated with PDT using half-fluence for fovea involving treatments (n=4) and full-fluence for extrafoveal treatments (n=5). The main outcome measures included anatomical changes measured on optical coherence tomography (OCT) and changes in best-corrected visual acuity (BCVA) after PDT.
RESULTS: All eyes had fovea involving serous retinal detachment on OCT, and six (67%) eyes had a history of three or more recurrences. The mean duration of current episode of CSC prior to PDT was 45 months (range: 3-131 months). The mean follow-up after PDT was 8 months (range: 3-18 months). Serous retinal detachment disappeared in all cases following PDT without any complications. One patient had a recurrence and was re-treated. Compared to the mean BCVA of 20/83 (logMAR 0.62) at baseline, the mean BCVA was 20/40 (logMAR 0.33) at 3 months (p=0.018), and 20/47 (logMAR 0.37) at last follow up (p=0.075). Visual acuity improved by at least two lines in three (33%) eyes.
CONCLUSIONS: Despite chronicity and recurrences seen in steroid-associated CSC, serous retinal detachment resolved in all cases, and a modest improvement in visual acuity was observed following PDT, at least for the short term. Given the difficulty of managing these cases, PDT as applied in this study may be an effective treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679080     DOI: 10.1136/bjo.2010.181149

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

Review 2.  Functional Polymer Nanocarriers for Photodynamic Therapy.

Authors:  Tuanwei Li; Lifeng Yan
Journal:  Pharmaceuticals (Basel)       Date:  2018-11-30

Review 3.  Advances in the treatment of central serous chorioretinopathy.

Authors:  Marwan A Abouammoh
Journal:  Saudi J Ophthalmol       Date:  2015-01-24

4.  Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment.

Authors:  Jin Young Kim; Ju Byung Chae; Jisoo Kim; Dong Yoon Kim
Journal:  J Ophthalmol       Date:  2018-07-22       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.